Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications.

[1]  D. Burr,et al.  THe effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib , 2009, Journal of Bone and Mineral Metabolism.

[2]  I. Sturm,et al.  Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. , 2008, Oral oncology.

[3]  A. Honecker,et al.  Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function , 2007, Journal of clinical pharmacology.

[4]  A. Pai,et al.  Oral bisphosphonate associated osteonecrosis of the jaws: three case reports , 2007, BDJ.

[5]  M. Dimopoulos,et al.  Bisphosphonate use and osteonecrosis of the jaw: Pharmacovigilance and reporting of this serious adverse event from the Research on Adverse Drug Events and Reports (RADAR) project , 2007 .

[6]  M. Aapro,et al.  International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. , 2007, European journal of cancer.

[7]  R. Civitelli,et al.  Safety Considerations with Bisphosphonates for the Treatment of Osteoporosis , 2007, Drug safety.

[8]  L. Elting,et al.  Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. , 2006, The Lancet. Oncology.

[9]  J. Kalmar,et al.  Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws , 2006, Annals of Internal Medicine.

[10]  K. Beattie,et al.  Tolerability of Different Dosing Regimens of Bisphosphonates for the Treatment of Osteoporosis and Malignant Bone Disease , 2006, Drug safety.

[11]  J. Body.  Bisphosphonates for malignancy-related bone disease: current status, future developments , 2006, Supportive Care in Cancer.

[12]  J. Epstein,et al.  Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. , 2005, Journal of the American Dental Association.

[13]  R. Marx,et al.  Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. , 2005, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[14]  R. Throndson,et al.  Bisphosphonate-induced osteonecrosis of the jaws. , 2005, Texas dental journal.

[15]  M. Neary,et al.  Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. , 2005, Clinical therapeutics.

[16]  D. Peterson,et al.  Bisphosphonate‐associated osteonecrosis of mandibular and maxillary bone , 2005, Cancer.

[17]  A. Licata.  Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates , 2005, The Annals of pharmacotherapy.

[18]  J. Zerwekh,et al.  Severely suppressed bone turnover: a potential complication of alendronate therapy. , 2005, The Journal of clinical endocrinology and metabolism.

[19]  T. J. Rosenberg,et al.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. , 2004, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[20]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Tripathy,et al.  448 Alleviation of bone pain with oral and intravenous ibandronate in women with metastatic breast cancer , 2003 .

[22]  R. Marx.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[23]  M. Lichinitser,et al.  Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.